Cargando…

The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity

The oncolytic adenovirus Delta24-RGD represents a new promising therapeutic agent for patients with a malignant glioma and is currently under investigation in clinical phase I/II trials. Earlier preclinical studies showed that Delta24-RGD is able to effectively lyse tumor cells, yielding promising r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleijn, Anne, Kloezeman, Jenneke, Treffers-Westerlaken, Elike, Fulci, Giulia, Leenstra, Sieger, Dirven, Clemens, Debets, Reno, Lamfers, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035348/ https://www.ncbi.nlm.nih.gov/pubmed/24866126 http://dx.doi.org/10.1371/journal.pone.0097495

Ejemplares similares

Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
por: Balvers, Rutger K., et al.
Publicado: (2014)

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity
por: Kleijn, Anne, et al.
Publicado: (2017)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
por: van Putten, Erik H.P., et al.
Publicado: (2022)

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
por: Balvers, Rutger K, et al.
Publicado: (2015)

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model
por: Jiang, Hong, et al.
Publicado: (2014)

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
por: Belcaid, Zineb, et al.
Publicado: (2020)

Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection
por: González-Morales, Andrea, et al.
Publicado: (2018)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory
por: Rivera-Molina, Yisel, et al.
Publicado: (2019)

A new insight into aggregation of oncolytic adenovirus Ad5-delta-24-RGD during CsCl gradient ultracentrifugation
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
por: Stavrakaki, Eftychia, et al.
Publicado: (2021)

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells
por: Kleijn, A., et al.
Publicado: (2016)

Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand
por: Jiang, Hong, et al.
Publicado: (2015)

HGG-15. THE IMIPRIDONE ONC201 IN COMBINATION WITH THE ONCOLYTIC ADENOVIRUS DELTA-24-RGD HAS A SYNERGISTIC EFFECT IN PRECLINICAL MODELS OF PHGGS AND DMGS
por: de la Nava, Daniel, et al.
Publicado: (2021)

Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
por: Fabro, Federica, et al.
Publicado: (2022)

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
por: Martínez-Vélez, Naiara, et al.
Publicado: (2019)

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
por: Ntafoulis, Ioannis, et al.
Publicado: (2022)

THER-02. EVALUATION OF THE ONCOLYTIC VIRUS DELTA24-RGD AS AN ANTI-TUMOR AGENT IN PRECLINICAL MODELS OF LOCALIZED AND DISSEMINATED AT/RT
por: Garcia-Moure, Marc, et al.
Publicado: (2020)

A novel oncolytic adenovirus based on simian adenovirus serotype 24
por: Cheng, Tao, et al.
Publicado: (2017)

Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates
por: Bots, Selas T.F., et al.
Publicado: (2022)

RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells
por: Yang, Y, et al.
Publicado: (2015)

Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus
por: Al-Zaher, Ahmed Abdullah, et al.
Publicado: (2018)

Anatomical Differences Determine Distribution of Adenovirus after Convection-Enhanced Delivery to the Rat Brain
por: Idema, Sander, et al.
Publicado: (2011)

The Multifaceted Role of Macrophages in Oncolytic Virotherapy
por: Hofman, Laura, et al.
Publicado: (2021)

Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures
por: Dekker, Lennard J. M., et al.
Publicado: (2022)

Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
por: Fabro, Federica, et al.
Publicado: (2022)

Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer
por: Mao, Li-jun, et al.
Publicado: (2018)

IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS
por: Labiano, Sara, et al.
Publicado: (2021)

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2
por: Venkatesan, Subramanian, et al.
Publicado: (2016)

Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity
por: Jiang, Hong, et al.
Publicado: (2023)

Oncolytic Adenoviruses in Gastrointestinal Cancers
por: Yokoda, Raquel T., et al.
Publicado: (2018)

Oncolytic Adenoviruses in Cancer Treatment
por: Alemany, Ramon
Publicado: (2014)

Oncolytic Adenovirus in Cancer Immunotherapy
por: Peter, Malin, et al.
Publicado: (2020)

Oncolytic Adenoviruses for Cancer Therapy
por: Tripodi, Lorella, et al.
Publicado: (2021)

Concepts in Oncolytic Adenovirus Therapy
por: Mantwill, Klaus, et al.
Publicado: (2021)

A Renaissance for Oncolytic Adenoviruses?
por: Blanchette, Paola, et al.
Publicado: (2023)

Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo
por: Zhu, Wei, et al.
Publicado: (2012)

Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation
por: Mao, Li-jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uvu0sqen3idod97n0jt017sha4